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Concerning the recent articles published in your journal on multifunctional nanosystem 
for cancer chemotherapy.1 It should be an admirable approach to kill cancer cells, 
with the least side effects on normal tissues and cells. During the past few decades, 
various chemotherapeutic agents, such as cyclophosphamide, fluorouracil, platinum-
based compounds, anthracycline, hydroxycamptothecin and paclitaxel, have been 
designed and proved to be effective toward cancer cells. However, regrettably, these 
drugs are non-targeted to cancer, and thus serious side effects to normal cells or 
tissues are unavoidable.2 Therefore, new drugs with selective cytotoxicity become an 
important research focus in cancer chemotherapy. Another obstacle for chemotherapy 
is the multidrug resistance. Actually, several targeted drugs such as RTK inhibitors, 
FTase inhibitors, tumor angiogenesis inhibitors, campath, avastin and erbitux, have 
been commercialized and widely used clinically.3 However, drug resistance seriously 
limited their anticancer efficacy. Nanotechnology-based approaches are anticipated to 
provide a new breakthrough for targeting cancer cells and bypassing their multidrug 
resistance.4
Zhang et al1 have developed two biodegradable novel drug delivery systems: 
poly(ethylene glycol)-modified docetaxel-lipid-based-nanosuspensions (pLNS), to 
increase the cycle time of the drugs within the body and enhance the accumulation 
of the drugs at the tumor sites, and targeted docetaxel-lipid-based-nanosuspensions 
(tLNS) using folate as the targeting ligand, which could target cancer cells overexpress-
ing folate receptor (FR). In vitro cytotoxicity was employed to evaluate the effects on 
human hepatocellular liver carcinoma HepG2 (FR-) and B16 (FR+) cells and the results 
showed that the cytotoxicity of tLNS against B16 cell lines was superior to pLNS, while 
no significant difference was observed for HepG2 cells. Moreover, in vivo anticancer 
efficacy evaluation showed that tLNS exhibited higher efficacy in reducing the tumor 
volume compared with pLNS. These results reveal the application potential of tLNS 
to enhance the accumulation of the drugs in cancerous tissues and cells.
Similarly, Du et al5 entrapped RGD peptide with poly(ethylene glycol)-modified 
stearic acid-grafted chitosan (PEG-CS-SA) nanomicelles via chemical reaction in 
the presence of N,N′-disuccinimidyl carbonate. Moveover, doxorubicin (DOX) was 
chosen as a model anticancer drug to investigate the drug entrapment efficiency, 
in vitro drug-release profile and anticancer activities of drug-loaded RGD-PEG-
CS-SA micelles in cells overexpressing integrins and integrin-deficient cells. Their 
results indicated that RGD-modified micelles could significantly increase the 
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intracellular DOX concentration and induce apoptosis in 
integrin-overexpressing BEL-7402 human hepatocellular 
carcinoma cells, but not in Hela human epithelial carcinoma 
cells. These results indicate that surface modification of 
PEG-CS-SA nanomicelles with RGD could be effective in 
selectively killing integrin-overexpressing tumor cells and 
minimizing the side effects on normal cells.
Nanosystem functionalized with carbohydrate, such as 
polysaccharides, a class of biopolymers naturally originated 
from plants or animals,6 could specifically interact with 
lectins that have been found overexpressed in the surface 
of cancer cells and malignant tissues.7 Therefore, we 
explored a simple method for functionalization of selenium 
nanoparticles (SeNPs) to enhance the cellular uptake 
and selective anticancer activity by surface decoration of 
Spirulina polysaccharides (SPS).8 The underlying molecular 
mechanisms were also investigated and the results revealed 
that SPS effectively increased the apoptosis-inducing activity 
of SeNPs. Moreover, we also demonstrated another strategy 
for preparation SeNPs through direct nanolization of gray 
Se by dissolving in PEG. The PEG-functionalized SeNPs 
exhibited higher potency toward doxorubicin-resistant 
hepatocellular carcinoma cells.9 Our results suggest that 
the strategy to use PEG200 as a surface decorator could be 
a highly efficient way to enhance the anticancer efficacy of 
nanomaterials.
In the recent relevant studies, Zhang et al10–12 explored the 
cell functions (including adhesion, proliferation, apoptosis 
and vascular endothelial growth factor (VEGF) secretion) 
decreasing activity of poly(lactic-co-glycolic acid) (PLGA) 
nanotopographies with different size and surface property to 
lung epithelial carcinoma cells and breast adenocarcinoma 
cells. The nanomaterials could be used to inhibit the growth, 
proliferation and angiogenesis of tumors, which open up new 
vistas for majorizating the surface and size of nanomedicine 
with antitumor properties.
As a novel idea of drug design in the future, nano-
medicine shows great potential in cancer chemotherapy. 
For instance, liposomes, nanomicelles, PLGA nanoparticles 
and carbon nanotubes, are now used as drug delivery carriers 
to improve the solubility, bioavailability and controled 
release of anticancer drugs. Moreover, nanocarriers pro-
vide a potential to conjugate ligands that target to different 
kinds of cancer cells or tissues. As a developing interdisci-
plinary, there are still some problems to be solved in cancer 
nanotechnology, such as the toxicity and safety, which require 
special consideration in future works.
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We are very grateful for allowing us the opportunity to 
respond. And we also appreciate the letter by Chen et al. In the 
letter, Dr Chen makes the important point that nanomedicine 
has the potential to increase the specificity of cancer treatment 
and bypassing their multidrug resistance.
Precisely so, nanotechnology, the new science of small, 
has a deep impact on solving many of the problems associated 
with conventional anticancer drugs based on their unique 
physical and biological properties.1,2 Two nanotechnology-
based cancer drugs, Doxil and Abraxane, are now readily 
accessible for cancer patients, though their potential toxicity 
and lower specificity should not be dismissed. Nevertheless, 
nanotechnologies for medical applications have been 
maturing. Researchers are aiming to develop more specific 
and safer nanomaterials to diagnose, treat and, eventually, 
prevent this disease.3
Recently, an innovative lipid-based nanocarrier, DTX 
loaded lipid based-nanosuspensions (LNS) has been devel-
oped in our group.4 This lipid-based nanocarriers holds 
the common advantages of lipid-based nanocarriers, while 
avoiding their shortcomings. (1) LNS have no drug leakage 
problems; (2) carry adequate amounts of drug and without 
excessive loading of the organism with foreign material; (3) 
formulate compounds that are insoluble in both water and 
oil; (4) the drug loading of LNS is high and the adminis-
tration volume is significantly reduced. More importantly, 
DTX-LNS was produced by high pressure homogenization 
which is the simplest method and has been successfully 
employed in large-scale production. Thus, DTX-LNS is a 
promising drug delivery system appropriate for large-scale 
production.
Nowadays, the idea behind cancer therapy that is being 
elucidated is that chemotherapy drugs can be specifically 
delivered to cancer cells by exploiting their same unique 
properties that made their detection, targeting and treatment 
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possible.5 An ideal, smart nanocarrier, would be attained by 
the more sophisticated design expected to be able to carry 
one or more drugs for therapy, specific moiety for targeting, 
imaging agent for detection, stimulus-sensitive element for 
controlled release of drugs, and a stabilizing polymer for 
biocompatibility.
Active targeting cancer therapy has the potential to change 
current cancer treatment scenarios.5 However, realizing tar-
geting and large-scale production at the same time is always 
a big challenge for nanosuspensions. To solve this puzzle, 
in our group, targeted DTX-LNS was produced by the lipid 
incorporation method. Consequently, targeted DTX-LNS, 
both appropriated for large-scale production and with high 
specificity, was obtained.6
Chemotherapeutic loaded nanomaterials targeting the 
tumor site are not only expected to eliminate adverse side 
effects, but also to pave the way of eradicating cancer and many 
other complex diseases by bringing a more effective, specific, 
and personalized nanomedicine.7 However, as mentioned in 
Dr Chen’s letter, we must also consider their current limitations 
and the important challenges for the future development of 
nanomaterials. Moreover, the design of these functional devices 
depends mainly on our understanding of the mechanisms 
involved in their cellular uptake and intracellular disposition.8 
Unfortunately, little is known about the fate of nanoparticles 
in the human body. The limited understanding of its cellular 
uptake would be a roadblock to its effective application. 
Thus, understanding of the cellular uptake mechanism is 
much required to design more efficient nanocarriers and has 
become arguably the hot topic in the molecular pharmaceutical 
field in the last 5–10 years, which is also one focus of our 
research efforts. Researchers are confident in the prospect of 
nanomaterials and are making efforts in this direction looking 
forward to effective targeting nanomedicine on the market.
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